These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 28143565)

  • 61. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
    Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
    Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
    Savaşan S; Buck S; Raimondi SC; Becton DL; Weinstein H; Chang M; Ravindranath Y
    Leuk Lymphoma; 2006 Oct; 47(10):2076-83. PubMed ID: 17071479
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
    Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antineoplastic Activity of Sodium Caseinate in a Cytarabine-Resistant Mouse Acute Myeloid Leukemia Cell Line.
    Aguiñiga-Sánchez I; Ledesma-Martínez E; Vázquez-Guerrero M; Hernández-Álvarez D; Velasco-García A; Rodríguez-Terán KM; Romero-Trejo D; Mendoza-Núñez VM; Macías-Zaragoza VM; Santiago-Osorio E
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339789
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Minderman H; Zhou Y; O'Loughlin KL; Baer MR
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
    Han J; Liu L; Yue X; Chang J; Shi W; Hua Y
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):477-83. PubMed ID: 24060341
    [TBL] [Abstract][Full Text] [Related]  

  • 70. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
    Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
    PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
    Becktell K; Houser K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):e38-e40. PubMed ID: 29668549
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
    Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
    Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
    Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
    Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY
    Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.